Granules India posted a strong second quarter for FY27, reporting a 39.2% increase in net profit to Rs 1,818.37 million. Revenue climbed over 20% to Rs 15,599.74 million. Alongside the robust financial performance, the company successfully completed a significant warrant conversion, raising over Rs 10,961 million in capital. While operations grow with new subsidiaries in Brazil and Mexico, investors are closely watching the USFDA inspection status at the Gagillapur facility.
Granules India Q2 Net Profit Climbs 39% to Rs 1,818 Million
Revenue grew 20.3% year-on-year to Rs 15,599.74 million; Net profit rose 39.2% to Rs 1,818.37 million.
Reader Takeaway: Strong double-digit growth and significant capital infusion are countered by pending USFDA regulatory responses at Gagillapur.
What just happened
Granules India Limited announced its financial results for the quarter ending September 30, 2026. The company saw a robust improvement in top-line and bottom-line figures, bolstered by a significant capital injection through the conversion of over 24.9 million warrants into equity shares, netting Rs 10,961.25 million.
Why this matters
The jump in profitability highlights sustained operational efficiency. Furthermore, the massive capital infusion strengthens the balance sheet, providing the company with liquidity to support its global expansion. The incorporation of two new subsidiaries—one in Brazil and one in Mexico—signals an aggressive push into Latin American markets.
Risks to watch
The Gagillapur facility received a Form FDA 483 following an August-September 2024 inspection. While the company clarified that observations do not pertain to data integrity or cross-contamination, the timeline for regulatory resolution remains a focal point for shareholders to avoid any potential impact on production capacity.
Context metrics
- Revenue from operations: Rs 15,599.74 million (Q2 FY27) vs Rs 12,969.88 million (Q2 FY26).
- Basic EPS: Rs 7.22 (up from Rs 5.38 in the year-ago period).
- Capital raised: Rs 10,961.25 million via warrant conversion at a premium of Rs 584 per share.
What to track next
Investors should monitor the company's communication with the USFDA regarding the Gagillapur plant and evaluate how the new international subsidiaries in Brazil and Mexico contribute to future revenue growth.